Last reviewed · How we verify
JTM201
At a glance
| Generic name | JTM201 |
|---|---|
| Sponsor | Jetema USA Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 1 Trial of JTM201 in Subjects With Post-stroke Upper Limb Spasticity (PHASE1)
- Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JTM201 CI brief — competitive landscape report
- JTM201 updates RSS · CI watch RSS
- Jetema USA Inc. portfolio CI